Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

2.820 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 309
Open 2.820
Bid (Size) 2.820 (1)
Ask (Size) 2.960 (30)
Prev. Close 2.820
Today's Range 2.820 - 2.820
52wk Range 1.380 - 19.69
Shares Outstanding 348,875,959
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
From Agenus Inc.
Via Business Wire
Here are the top movers in Tuesday's session.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill

Performance

YTD
-8.7%
-8.7%
1 Month
+68.9%
+68.9%
3 Month
-25.0%
-25.0%
6 Month
-36.1%
-36.1%
1 Year
-62.0%
-62.0%

More News

Read More
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
From Agenus Inc.
Via Business Wire
Earnings Scheduled For November 12, 2024
Via Benzinga
Insights Ahead: Agenus's Quarterly Earnings
Via Benzinga
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
From Agenus Inc.
Via Business Wire
Agenus (AGEN) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
From Agenus Inc.
Via Business Wire
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
From Agenus Inc.
Via Business Wire
Earnings Scheduled For March 11, 2025
Via Benzinga
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
From Agenus Inc.
Via Business Wire
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
From Agenus Inc.
Via Business Wire
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
From Agenus Inc.
Via Business Wire
CORRECTING and REPLACING Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
From Agenus Inc.
Via Business Wire
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas
From Agenus Inc.
Via Business Wire
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
From Agenus Inc.
Via Business Wire
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
From Agenus Inc.
Via Business Wire
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
From Agenus Inc.
Via Business Wire
Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development
Via Benzinga
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
From Agenus Inc.
Via Business Wire
Agenus (AGEN) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
From Agenus Inc.
Via Business Wire
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
From Agenus Inc.
Via Business Wire
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Agenus to Contact Us to Have Their Losses Evaluated Today
From Faruqi & Faruqi LLP
Via GlobeNewswire

Frequently Asked Questions

Is Agenus Inc. - Common Stock publicly traded?
Yes, Agenus Inc. - Common Stock is publicly traded.
What exchange does Agenus Inc. - Common Stock trade on?
Agenus Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Agenus Inc. - Common Stock?
The ticker symbol for Agenus Inc. - Common Stock is AGEN on the Nasdaq Stock Market
What is the current price of Agenus Inc. - Common Stock?
The current price of Agenus Inc. - Common Stock is 2.820
When was Agenus Inc. - Common Stock last traded?
The last trade of Agenus Inc. - Common Stock was at 04/24/25 04:00 PM ET
What is the market capitalization of Agenus Inc. - Common Stock?
The market capitalization of Agenus Inc. - Common Stock is 983.83M
How many shares of Agenus Inc. - Common Stock are outstanding?
Agenus Inc. - Common Stock has 984M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.